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Parkin E3 ubiquitin-ligase activity and its role in mitochondria homeostasis are thought to play a role in
Parkinson’s disease (PD). We now report that AF-6 is a novel parkin interacting protein that modulates
parkin ubiquitin-ligase activity and mitochondrial roles. Parkin interacts with the AF-6 PDZ region through
its C-terminus. This leads to ubiquitination of cytosolic AF-6 and its degradation by the proteasome. On the
other hand, endogenous AF-6 robustly increases parkin translocation and ubiquitin-ligase activity at the mito-
chondria. Mitochondrial AF-6 is not a parkin substrate, but rather co-localizes with parkin and enhances mito-
chondria degradation through PINK1/parkin-mediated mitophagy. On the other hand, several parkin and PINK1
juvenile disease-mutants are insensitive to AF-6 effects. AF-6 is present in Lewy bodies and its soluble levels
are strikingly decreased in the caudate/putamen and substantia nigra of sporadic PD patients, suggesting that
decreased AF-6 levels may contribute to the accumulation of dysfunctional mitochondria in the disease. The
identification of AF-6 as a positive modulator of parkin translocation to the mitochondria sheds light on the
mechanisms involved in PD and underscores AF-6 as a novel target for future therapeutics.
INTRODUCTION
Parkinson’s disease (PD) is characterized by the degeneration
of dopaminergic neurons in the substantia nigra and the pres-
ence of cytoplasmic inclusions called Lewy bodies (1). Most
PD cases are sporadic, but several genes are mutated in heredi-
tary forms of PD, providing clues about the mechanisms
involved in the disease (1,2). Mutations in parkin are a
common cause of familial PD and are responsible for most
of autosomal recessive juvenile parkinsonism; referred here
as juvenile PD (3). Although juvenile PD cases have few or
absent Lewy bodies (4), parkin is present in the Lewy
bodies of sporadic PD cases (5–7).
Parkin is an E3 enzyme (8) that belongs to the class of
Ring-IBR-Ring ubiquitin-ligases (9,10). Parkin ubiquitinates
different proteins, such as synphilin-1, p38, CDCrel, Pael-R,
among others (4). Interaction of parkin with synphilin-1
increases the formation of a-synuclein/synphilin-1 inclusions
and may contribute to Lewy body formation (11). Parkin also
associates through its C-terminus with the PDZ-containing pro-
teins CASK/LIN-2 and PICK1 (12,13). The interaction of
parkin with these PDZ domain proteins targets parkin to the
postsynaptic protein complex (12).
Since parkin ubiquitin-ligase activity is decreased in both
juvenile and sporadic PD (14–16), it is possible that toxic
protein accumulation in PD leads to dopaminergic death. In
agreement, the parkin substrate p38 accumulates in parkin
knockout mice and in both sporadic and juvenile PD cases
(17). In addition, parkin interacts with Paris, a protein
that accumulates in PD patients and regulates the levels of
the transcription factor PGC-1a (18). Supporting a decreased
function of parkin in the disease, nitrosylation of parkin in
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PD leads to decreased ubiquitin-ligase activity at late time
points (14,15). Moreover, phosphorylation by Cdk5 decreases
parkin ubiquitin-ligase activity (19), while suppression of
Cdk5 activity in mice prevents the dopaminergic toxicity
promoted by the PD-related toxin 1-methyl-4-phenyl-1,2,36-
tetrahydropyridine (20).
Besides regulating the degradation of substrates, parkin
protects neurons from several insults, including a-synuclein
toxicity and oxidative stress in neurons (21). Parkin also
plays an important role in maintaining mitochondrial function.
Suppression or knockout of parkin expression in mice,
Drosophila or human cells leads to severe mitochondrial dys-
function (22,23). Knockout of PINK1, another protein mutated
in familial PD (24), also leads to mitochondrial dysfunction.
Strikingly, the effects of PINK1 knockout are reversed by
parkin overexpression (25–28), indicating that parkin works
downstream of PINK1 in a common pathway involved in
maintaining optimal mitochondrial function. Additionally,
parkin translocates to damaged mitochondria, in a process
mediated by PINK1. Once on the mitochondria, parkin recruits
autophagic vesicles leading to subsequent mitophagy (29–32).
The regulation of parkin translocation to the mitochondria,
however, is still poorly understood. In addition to PINK1, it
is likely that the process requires the concert action of add-
itional partners. We now sought to discover new parkin inter-
acting partners that specifically affect the mitochondrial roles
of parkin. We report that parkin interacts with AF-6, which ro-
bustly increases its translocation to the mitochondria. AF-6
activates parkin ubiquitin-ligase activity and promotes parkin-
mediated mitochondrial clustering and mitophagy. We found
that cytosolic AF-6 is also a parkin substrate for the prote-
asome. AF-6 is present in Lewy bodies and its soluble levels
are decreased in sporadic PD brains, suggesting that AF-6 de-
ficiency may contribute to the mitochondrial dysfunction
observed in the disease.
RESULTS
AF-6 is expressed in the brain and is important for dendritic
spine plasticity (33). Similar to the parkin-interacting proteins
CASK and PICK1 (12,13), AF-6 contains a PDZ domain and
its levels are correlated with parkin in certain types of cancers
(34). This led us to investigate a possible direct interaction of
parkin with AF-6. For this purpose, we incubated lysates of
HEK293 cells transfected with HA-parkin with recombinant
glutatione S-transferase (GST)-AF-6 (amino acids 849–
1190), encompassing the AF-6 PDZ domain. We observed
that parkin was pulled-down by AF-6 but not by a control
protein (Fig. 1A), indicating that parkin and AF-6 interact in
vitro.
Using an algorithm to predict the interaction with PDZ
domains (35), we found that the last three amino acids of
parkin likely interact with the AF-6 PDZ region. To test the
in silico prediction, we generated a parkin construct devoid of
the last three amino acids (parkin D3). However, since the dele-
tion of parkin’s last amino acids promotes massive aggregation
of parkin and inclusion formation per se (36), we carried out im-
munocytochemistry experiments to evaluate the interaction with
AF-6. Since wild-type parkin does not form inclusion unless
under conditions of proteasome inhibition (19,37), the
experiments were carried out in the presence of lactacystin to
allow a comparable amount of inclusion formation among the
different parkin constructs. We found that AF-6 co-aggregates
with inclusions of wild-type parkin upon proteasome inhibition
but not with inclusions of parkin D3 (Fig. 1B and C). To further
confirm that the C-terminus of parkin is responsible for the
interaction with AF-6, we mutated the last two amino acid resi-
dues of parkin from FDV to FAA and found that in the presence
of lactacystin, AF-6 co-aggregates to a smaller extent with
parkin phenylalanine, alanine, alanine (FAA) in comparison to
wild-type parkin (Fig. 1C).
Since parkin FAA did not aggregate as much as parkinD3, we
were able to carry out a series of biochemical experiments in
order to confirm the role of parkin’s C-terminal in the interaction
with AF-6. We investigated the ability of AF-6 to interact with
parkin FAA by carrying out co-immunoprecipitation experi-
ments from HEK293-transfected cells. We found that AF-6
co-immunoprecipitated with wild-type parkin but much less ef-
ficiently with parkin FAA (Fig. 1D), further supporting the role
of the parkin C-terminal region in the interaction. AF-6 also did
not co-immunoprecipitate with beads alone (Fig. 1D), indicat-
ing the specificity of the interactions. As an additional control,
we found that the unrelated protein FKBP12 does not
co-immunoprecipitate with parkin (Fig. 1E), giving further indi-
cation that the association with AF-6 is specific. Taken together,
the results indicate that parkin–AF-6 interaction is mostly
mediated by interaction of parkin C-terminal with the PDZ
of AF-6.
Next, we carried out co-immunoprecipitation experiments
using rat brain tissues and found that endogenous AF-6
co-immunoprecipitates with parkin but not with the control
IgG (Fig. 1F), supporting the in vivo interaction between
parkin and AF-6.
In order to determine if AF-6 is a parkin substrate, we
carried out in vivo ubiquitination experiments where we
immunoprecipitated AF-6 and found that parkin promotes its
ubiquitination in a specific manner (Fig. 2A). In agreement,
parkin FAA is less efficient than wild-type parkin to ubiquiti-
nate AF-6 (Fig. 2B). We next investigated whether the ubiqui-
tination by parkin leads to AF-6 degradation, and found that
increasing amounts of wild-type parkin decrease AF-6
steady-state levels while parkin FAA promotes a smaller de-
crease of AF-6 steady-state levels (Fig. 2C). Pulse-chase ana-
lysis of 35S-labeled immunoprecipitated AF-6 revealed that
parkin decreases AF-6 half-life (Fig. 2D), indicating that ubi-
quitination by parkin leads to AF-6 degradation.
To further determine the relevance of AF-6 degradation
mediated by parkin, we carried out experiments in which we
knocked down the expression of endogenous parkin using
shRNA. We found that shRNA to parkin increases the
steady-state levels of overexpressed (Fig. 3A) as well as of en-
dogenous AF-6 (Fig. 3B), indicating that AF-6 may represent
an authentic substrate of parkin. Furthermore, transfection of
shRNA-resistant parkin rescued the shRNA effects on AF-6
levels, indicating the specificity of the shRNA used
(Fig. 3C). Moreover, an additional E3 ubiquitin-ligase that
belongs to the group of parkin Ring-IBR-Ring ligases,
HHARI (38), does not decrease AF-6 steady-state levels
(Fig. 3D), confirming the specificity of AF-6 ubiquitination
and degradation by parkin.
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Since parkin translocation to the mitochondria is thought to
play a role in PD, we investigated whether AF-6 modulates this
process. For this, we purified mitochondrial fractions
of transfected cells and observed that AF-6 increases the levels
of parkin at the mitochondria by almost 5-fold (Fig. 4A and B).
AF-6 had a much less effect on the levels of the mitochondrial
marker voltage-dependent anion channel (VDAC), indicating
that the increase in mitochondrial parkin is not due to higher mito-
chondria biogenesis (Fig. 4A and B). Furthermore, we found that
AF-6 co-translocates along with parkin to the mitochondria
(Fig. 4A), further supporting their biochemical interaction. The
effect of AF-6 in increasing parkin translocation to the mitochon-
dria was also observed in immunocytochemistry experiments, as
shown by the increased co-localization of parkin with the mito-
chondrial marker GFP-mito promoted by AF-6 when compared
with a control protein (Fig. 4C).
We also carried out the converse experiments where we
investigated the effect of parkin on AF-6 translocation to the
mitochondria. We found that parkin transfection, at levels
that do not degrade cytosolic AF-6 (1 mg, Fig. 2C), increases
the levels of AF-6 at the mitochondria (Fig. 4D and E). More-
over, AF-6 partly co-localizes with GFP-mito and this
co-localization is increased in the presence of parkin
(Fig. 4F and G), confirming the specific translocation of
AF-6 to the mitochondria. Thus, in contrast to the cytosolic
AF-6, mitochondria-associated AF-6 is not degraded by
parkin.
We next investigated how AF-6 interferes with parkin
ubiquitin-ligase activity at the mitochondria. We isolated cyto-
solic and mitochondrial fractions from transfected cells, immu-
noprecipitated parkin from both fractions, and determined
parkin ubiquitin-ligase activity by its auto-ubiquitination
levels relative to immunoprecipitated parkin. We found that
AF-6 robustly increases the amount of auto-ubiquitinated
parkin in the mitochondria compared with LacZ (Fig. 5A and
B). Even though the translocation of parkin to the mitochondria
per se leads to an increase in its ubiquitin-ligase activity
(Fig. 5A and B) and (29), AF-6 clearly potentiates this effect,
indicating a direct effect on parkin ubiquitin-ligase activity at
the mitochondria.
The activation of PINK1/parkin pathway promotes the clus-
tering of mitochondria, which is subsequently degraded by
mitophagy (32,39). In agreement, we found that parkin and
PINK1 overexpression promotes massive clustering of mito-
chondria (Fig. 6A). Next, we tested the effect of AF-6 on
the PINK1/parkin pathway. We found that in addition to
Figure 1. AF-6 interacts with parkin. (A) Extracts of HEK293 cells transfected with HA-parkin were incubated with a GST-AF-6 PDZ domain (amino acids
849–1190) or the control GST-FKBP12. Binding was analyzed with an anti-HA antibody. GST fusion proteins used in the experiments were determined by
staining the membranes with Ponceau S (lower panel). (B) AF-6 co-localizes with inclusions of wild-type parkin but not with a D3 C-terminal mutant.
HEK293 cells were co-transfected with HA-parkin (wild-type and D3 mutant), myc-AF-6, and treated for 16 h with 10 mM lactacystin. Immunocytochemistry
was carried out with anti-HA (red, A) and anti-myc antibodies (green, B). Scale bar, 25 mm. (C) HEK293 cells were co-transfected with HA-parkin (wild-type,
D3 and FAA mutants) and myc-AF-6, and treated for 16 h with 10 mM lactacystin. Immunocytochemistry was carried out as in (B). The plot shows the percentage
of aggregates in which AF-6 co-localizes with the different parkin constructs. Error bars represent standard error of three to six independent experiments.
∗∗, ∗∗∗Significantly different from wild-type parkin at P , 0.01 and at P , 0.001, respectively. (D) HEK293 cells were co-transfected with myc-AF-6 in the
presence of HA-parkin, HA-parkin FAA or GFP. HA-parkin was immunoprecipitated using an anti-HA antibody and samples were analyzed with an
anti-myc antibody. The levels of HA-parkin immunoprecipitates were determined using anti-HA antibody (middle panel), while the input levels of
myc-AF-6 were determined with an anti-myc antibody (lower panel). (E) HEK293 cells were co-transfected with HA-parkin and myc-AF-6 or myc-FKBP12
as control. HA-parkin was immunoprecipitated using anti-HA and samples were analyzed with an anti-myc antibody. Co-immunoprecipitation of myc-AF-6
was observed with parkin but not with the control protein FKBP12 (upper and middle panels). The levels of HA-immunoprecipitates were revealed using an
anti-HA antibody (lower panel). (F) Endogenous parkin was immunoprecipitated from rat brain lysate using an anti-parkin antibody and co-immunoprecipitation
was revealed with an anti-AF-6 antibody. Co-immunoprecipitation of AF-6 was not observed in control coupled to IgG. The figures are representative of three
independent experiments.
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increase parkin translocation (Fig. 6B and C), AF-6 signifi-
cantly increased the mitochondrial clustering mediated by
parkin and PINK1 (Fig. 6B and D). Additionally, AF-6 was in-
effective in increasing the translocation of parkin FAA to the
mitochondria as well as in increasing mitochondrial clustering
in the presence of this mutant (Fig. 6C and D), a result com-
patible with the decreased ability of AF-6 to interact
with parkin FAA (Fig. 1D). Moreover, we observed
similar effects of AF-6 on translocation of parkin and mito-
chondrial clustering in HEK293 cells and HeLa cells (data
not shown).
To confirm the role of endogenous AF-6, we employed an
shRNA strategy. Knockdown of endogenous AF-6 decreased
both parkin translocation and mitochondrial clustering
(Fig. 6E and F). To rule off-target effects of the shRNA to
AF-6, we examined whether the reduced parkin translocation
and mitochondrial clustering could be rescued by full-length
shRNA-resistant AF-6 (Fig. 6G and H). Indeed, expression
of shRNA-resistant AF-6 rescued parkin translocation and
mitochondrial clustering in the presence of the shRNA
(Fig. 6E and F), suggesting that AF-6 works as an endogenous
regulator of the PINK1/parkin pathway.
Depolarization by the ionophore carbonyl cyanide m-chlor-
ophenyl hydrazone (CCCP) promotes the translocation of
parkin to the mitochondria (30,31). To determine whether
AF-6 also increases the translocation of parkin to depolarized
mitochondria, we transfected HeLa cells stably expressing
GFP-parkin with AF-6. We found that AF-6 significantly
increases the translocation of parkin even to mitochondria
depolarized by CCCP (Fig. 6I and J), indicating that the two
processes are additive.
We next examined whether AF-6 affects mitophagy. We
found that AF-6 increases the amount of PINK1/parkin-
mediated mitophagy, as shown by the lower number of mito-
chondria in cells co-transfected with AF-6 when compared
with cells co-transfected with control LacZ, as assessed
by the mitochondrial marker Tom-20 (Fig. 7A and B).
The effect of AF-6 on mitophagy was confirmed as siRNA-
mediated AF-6 knockdown decreases PINK1/parkin-dependent
mitophagy (Fig. 7C). Moreover, the decrease in mitophagy
Figure 2. Cytosolic AF-6 is a parkin substrate. (A) HEK293 cells were co-transfected with HA-AF-6, Flag-ubiquitin, in the presence of myc-parkin or
myc-FKBP12. Cells were incubated for 12 h with 10 mM lactacystin, and HA-AF-6 was immunoprecipitated with an anti-HA antibody. Ubiquitination of
AF-6 was detected with an anti-Flag antibody. The second panel shows the levels of immunoprecipitated AF-6 using an anti-HA antibody. Third and fourth
panels show the input consisting of total ubiquitinated proteins and parkin, respectively. (B) HEK293 cells were co-transfected with myc-AF-6 and
Flag-ubiquitin, in the presence of HA-parkin, HA-parkin FAA or Flag-LacZ. Cells were incubated for 16 h with 10 mM lactacystin, and myc-AF-6 was immu-
noprecipitated with an anti-myc antibody. Ubiquitination of AF-6 was detected with an anti-Flag antibody. The second panel shows the levels of immunopre-
cipitated AF-6 using an anti-AF-6 antibody. Third and fourth panels show the input consisting of total ubiquitinated proteins and parkin, respectively. (C) Parkin
lowers the steady-state levels of AF-6. HEK293 cells were transfected with myc-AF-6 and increasing amounts of HA-parkin or HA-parkin FAA. The steady-state
levels of myc-AF-6 from total cell lysates were detected by western blot using an anti-myc antibody (upper panel). The expression levels of parkin (WT and
FAA) were determined using an anti-parkin antibody. Loading control was monitored with an anti-actin antibody (lower panel). (D) Parkin decreases the half-life
of cytosolic AF-6. HEK293 cells transfected with HA-AF-6 and myc-parkin were chased for the indicated time points, and HA-AF-6 was immunoprecipitated
using an anti-HA antibody. Immunoprecipitates were analyzed by SDS–PAGE and autoradiography (upper panels). Graph shows the quantification of remaining
AF-6 in the presence of LacZ (open circle) or parkin (filled circle) at indicated time points. Error bars represent standard error of three independent experiments.
∗∗Significantly different from control at P , 0.01.
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observed when AF-6 is knocked down is specific since the
transfection of siRNA-resistant recombinant AF-6 rescues this
effect (Fig. 7C–E). Therefore, AF-6 seems to fully activate
the PINK1/parkin pathway, from the initial steps of parkin
translocation through mitochondrial degradation by mitophagy.
Some parkin juvenile disease-mutants are unable to translo-
cate to the mitochondria (29,40), while PINK1 mutations
disrupt parkin recruitment to the mitochondria (31). We next
sought to investigate whether AF-6 could overcome the
defects of parkin and PINK1 mutants. Among the five differ-
ent parkin mutants analyzed, AF-6 was only able to partially
increase the translocation of the T240R mutant (Fig. 8A–C).
Although AF-6 also partially increases the mitochondrial clus-
tering with T240R (Fig. 8C), it fails to increase the mitophagy
with this mutant (data not shown). Furthermore, AF-6 does not
increase parkin translocation and mitochondrial clustering
when in the presence of the PINK1 G309D mutant (Fig. 8B
and C), suggesting that AF-6 requires intact PINK1 to
promote the mitochondrial translocation of parkin.
We also characterized the relevance of AF-6 to PD by ana-
lyzing its expression in the brain of rats and patients. We
found that AF-6 is widely expressed in the rat brain, including
the midbrain that contains the substantia nigra and is affected
in PD (Fig. 9A). We next investigated the levels of AF-6 in PD
brains. We found that the steady-state levels of soluble AF-6
are significantly lower in the caudate/putamen as well as in
the substantia nigra of PD patients (Fig. 9B–E). We also
detected AF-6 in 25% of mature Lewy bodies and in occa-
sional Lewy neurites in the substantia nigra of the four PD
brains analyzed (Fig. 9F).
DISCUSSION
We found that parkin interacts with the PDZ-containing
protein AF-6 in vitro and in vivo. Parkin promotes the ubiqui-
tination and degradation of cytosolic AF-6. Knockdown of
parkin leads to accumulation of endogenous AF-6, indicating
that cytosolic AF-6 is a parkin substrate. On the other hand,
the interaction of AF-6 with parkin has a different role at
the mitochondria where parkin does not degrade AF-6. We
found that endogenous AF-6 increases the translocation of
parkin to the mitochondria, enhancing its ubiquitin-ligase ac-
tivity, and promoting mitochondrial clustering and mitophagy.
Our data indicate that AF-6 is a positive modulator of parkin
recruitment and activity at the mitochondria via the parkin/
PINK1 pathway. The substantial decrease in soluble AF-6 in
sporadic PD brain tissues indicates that AF-6 deficiency may
contribute to the disruption of mitochondrial homeostasis
thought to occur in PD.
AF-6 is important for cell–cell contact by the formation and
maintenance of adherent and tight junctions (41,42). Neverthe-
less, AF-6 translocates to the nucleus in a growth factor-
regulated and cell cycle dependent fashion, suggesting that
AF-6 may also affect cellular growth (43). Moreover, AF-6
also regulates activity-dependent dendritic spine plasticity in
cortical neurons (33). Thus, our findings of AF-6 translocation
to the mitochondria and its ability to positively modulate the
parkin/PINK1 pathway fits with the multiple roles of AF-6
in signal transduction.
The interaction of parkin with the PDZ domain of AF-6
mostly depends on its C-terminal region which is in accord-
ance with classical PDZ interaction mechanisms (44). In
agreement, deletion of parkin last three amino acid residues
prevented its co-localization with AF-6. Since the deletion
of these last three amino acids promotes a drastic aggregation
of parkin, we further confirmed the specificity of the inter-
action by mutating parkin’s last two amino acids (parkin
FAA), which was less prone to aggregation. Parkin FAA
exhibited reduced interaction and co-localization with AF-6,
and promoted less ubiquitination and degradation of AF-6
compared with wild-type parkin. Moreover, AF-6 did not in-
crease parkin FAA translocation to the mitochondria and mito-
chondrial clustering, further supporting the notion that the
interaction of AF-6 with parkin requires the interaction
between parkin C-terminus and the AF-6 PDZ domain.
Parkin also interacts with the PDZ-containing proteins,
Figure 3. Endogenous parkin regulates AF-6 levels. (A) Knockdown of parkin
increase the steady-state levels of overexpressed AF-6. HEK293 cells were
transfected with HA-AF-6 in the presence of shRNA control or shRNA to
parkin. HA-AF-6 from total cell lysates was detected using an anti-HA anti-
body (upper panel). The presence of parkin was monitored with an anti-parkin
antibody (middle panel). Loading control was monitored with an anti-actin
antibody (lower panel). (B) Knockdown of parkin increases the steady-state
levels of endogenous AF-6. HEK293 cells were transfected with shRNA
control or shRNA to parkin. AF-6 from total cell lysates was detected using
an anti-AF-6 antibody (upper panel). The presence of parkin was monitored
with an anti-parkin antibody (middle panel). Loading control was monitored
with an anti-actin antibody (lower panel). (C) Transfection of shRNA-resistant
HA-parkin rescued the effects of shRNA-mediated parkin knockdown.
HEK293 cells were transfected with shRNA to parkin, in the presence of
2 mg HA-parkin or shRNA-resistant HA-parkin. AF-6 from total cell lysates
was detected using an anti-AF-6 antibody (upper panel). Parkin was detected
with an anti-HA antibody (middle panel), while loading control was monitored
with an anti-actin antibody (lower panel). (D) AF-6 steady-state levels are not
affected by the Ring-IBR-Ring E3 ubiquitin-ligase HHARI. HEK293 cells
were transfected with myc-AF-6 in the presence of Flag-parkin or
Flag-HHARI. The second and third panels show the levels of parkin and
HHARI with their specific antibodies. Loading control was monitored with
an anti-actin antibody (fourth panel). Percent of AF-6 levels corrected by
the levels of actin is shown at the bottom of each figure.
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CASK/LIN-2 and PICK1 (12,13), which are known as synap-
tic proteins. Their interaction implies that parkin has a role in
regulating some aspects of the synaptic transmission (45,46).
In this framework, we hypothesize that the interaction of
parkin with different PDZ-containing proteins may represent
a modus operandi, allowing it to carry out various functions
at different cell compartments.
The translocation of parkin to the mitochondria activates its
E3 ubiquitin-ligase activity (29). In agreement, we found that
parkin is indeed more active at the mitochondria and that AF-6
increases even more its activity at this organelle. Since the
interaction of parkin N-terminal ubiquitin-like domain with
the C-terminus prevents its activation (47), it is possible that
binding to the mitochondria weakens the auto-inhibition
of parkin by altering the interaction between the N- and
C-terminal regions. In this framework, binding of AF-6 to
the C-terminus of parkin seems to be required to fully activate
parkin by relieving its auto-inhibition at the mitochondria.
Moreover, as proteasomal activation at the mitochondria is
an essential step prior to mitophagy (48,49), activation of
Figure 4. AF-6 promotes parkin translocation to the mitochondria. (A) HEK293 cells were transfected with HA-parkin in the presence of myc-AF-6 or
myc-LacZ, and lysates were processed to isolate cytosolic and mitochondrial fractions. Translocation of parkin to the mitochondria by AF-6 was determined
with an anti-parkin antibody (first panel). The second panel shows the presence of myc-AF-6 in the mitochondrial fraction as well (anti-AF-6 antibody). The
third panel shows that myc-LacZ does not translocate to the mitochondria in the presence of parkin (anti-myc antibody). The purity of cytosolic and mitochon-
drial fractions was determined with anti-GAPDH and anti-VDAC, respectively. (B) HEK293 cells were transfected with HA-parkin in the presence of myc-AF-6
or myc-LacZ. Cell lysates were processed as in (A). The presence of parkin and VDAC in mitochondrial fraction was determined by ImageMaster. The graph
shows the fold increase in mitochondrial parkin and VDAC promoted by AF-6 when compared with LacZ control. Error bars represent standard error of four
independent experiments. (C) SH-SY5Y cells were transfected with HA-parkin and the mitochondrial marker GFP-mito, in the presence of either myc-AF-6 or
myc-LacZ. Immunocytochemistry and confocal microscopy were carried out with an anti-HA antibody to reveal HA-parkin (red, A and D) and GFP-mito fluor-
escence (green, B and E). Scale bar, 25 mm. (D) HEK293 cells were transfected with HA-AF-6 in the presence of 1 mg myc-parkin or myc-LacZ, and lysates
were processed to isolate mitochondrial fractions (right panels). Total inputs are shown in left panels. Translocation of AF-6 to the mitochondria by parkin was
determined with an anti-AF-6 antibody (first panel). The second panel shows the presence of myc-parkin but not myc-LacZ in the mitochondrial fraction. The
loading of mitochondrial fractions was determined with anti-VDAC. (E) HEK293 cells were transfected with HA-AF-6 in the presence of myc-parkin or
myc-LacZ. Cell lysates were processed as in (A). The graph shows the fold increase in mitochondrial AF-6 and VDAC promoted by parkin when compared
with LacZ control. Error bars represent standard error of three independent experiments. (F) SH-SY5Y cells were transfected with HA-parkin, myc-AF-6
and GFP-mito. Immunocytochemistry was carried out with anti-myc antibody. Confocal microscopy pictures depict both myc-AF-6 (red, A) and GFP-mito
(green, B). Scale bar, 25 mm. (G) SH-SY5Y cells were transfected with HA-AF-6 and GFP-mito, and also with myc-parkin or myc-LacZ. Immunocytochemistry
was carried out with anti-HA antibody and analyzed as in F. The graph shows the increase in mitochondrial AF-6 promoted by parkin when compared to LacZ
control. Error bars represent standard error of three independent experiments. ∗∗Significantly different from VDAC at P , 0.01 (B and E). ∗∗Significantly dif-
ferent from control at P , 0.01 (G).
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parkin ubiquitin-ligase activity at the mitochondria may repre-
sent the mechanism by which AF-6 activates mitophagy as
well. Parkin increases AF-6 translocation and levels of AF-6
at the mitochondria. For these experiments, we used a low
parkin concentration that does not degrade cytosolic AF-6. It
is not clear why mitochondrial AF-6 is not degraded by mito-
chondrial parkin, while cytosolic AF-6 is a parkin substrate.
One possibility is that binding to the mitochondria shields
AF-6 ubiquitination sites or that parkin ligase activity at the
mitochondria is diverted toward more effective substrates in-
cluding a plethora of outer membrane mitochondrial proteins
(48,50,51).
A few proteins were shown to influence parkin/PINK1
pathway. For instance, Ambra1 affects the mitochondrial
clearance but not the translocation of parkin (52). Yet, AF-6
seems to be an unique activator of the parkin/PINK1
pathway since it promotes all key steps, from the translocation
of parkin to the mitochondria, through parkin ubiquitin-ligase
activation to mitochondrial clustering and mitophagy. Thus,
AF-6 may be important to maintain proper mitochondrial
homeostasis under normal conditions. It is noteworthy that
AF-6 soluble levels are decreased in affected PD brain
areas, implying that AF-6 deficiency may contribute to
mitochondrial dysfunction thought to occur in PD (53). The
presence of AF-6 in Lewy bodies indicates that it may be
aggregated and inactive at these structures. Like AF-6, the
soluble forms of the synphilin-1 isoform, synphilin-1A
and USP9X are decreased in a-synucleinopathies (54,55).
Thus, it is possible that depletion of critical proteins, like
AF-6, from the cytosol of affected neurons may have
more implications to the pathogenesis of PD than previously
anticipated.
Depolarization by the mitochondrial uncoupler CCCP
recruits parkin to the mitochondria, followed by mitochondrial
clustering and mitophagy (30,32). Although the real purpose
of parkin translocation to the mitochondria is still under
debate (56,57), its translocation depends on the presence of
PINK1. Depolarization of mitochondria by CCCP stabilizes
PINK1 uncleaved form, causing it to stay longer at the mem-
brane, and allowing it to recruit more efficiently parkin to the
mitochondria (31). We have shown that AF-6 increases the
translocation of parkin to the mitochondria and that both
PINK1 overexpression and mitochondrial depolarization by
CCCP intensifies this effect. On the other hand, AF-6 is
unable to properly activate parkin and PINK1 mutants
(29,31,40), indicating that the juvenile disease mutations are
insensitive to AF-6. The data are consistent with the notion
that AF-6 works in concert with parkin and PINK1 to
promote mitochondrial degradation. The finding that AF-6
levels are decreased in PD brains suggests that it may contrib-
ute to the mitochondrial dysfunction observed in the disease.
Strategies to increase AF-6 levels represent now a tantalizing
novel target for future therapeutics.
MATERIALS AND METHODS
Materials
[35S]Methionine/cysteine was obtained from Perkin-Elmer.
Lipofectamine 2000 was purchased from Invitrogen. A com-
plete protease inhibitor cocktail was obtained from Roche.
All other reagents were purchased from Sigma.
Cell culture and transfections
HEK293 and SH-SY5Y cells were grown in DMEM contain-
ing 10% fetal bovine serum in a 5% CO2 atmosphere.
Cells were transiently transfected with N-terminal-tagged
pRK5 and pFLAG-CMV-2 plasmids utilizing Lipofectamine
2000 and processed after 36 h. For experiments using
small-interference RNAs, the cells were transfected with
shParkin (5′-GATCCCCGTCACGAAACAAATGCCTCTTC
AAGAGAGAGGCATTTGTTTCGTGACTTTTTA-3′; Oli-
goengine), shAF-6 (5′-CCGGCC AAAGAAATTGCCTGGTG
AT CTCGAGATCACCAGGCAATTTCTTTGGTTTTTG-3′;
Sigma), siAF-6 (5′-GUAUGCACCUGAUGACAUUdTdT-3′;
Ambion) or scrambled shRNA and siRNA controls using Lipo-
fectamine 2000 as previously described (19).
For the shRNA rescue experiments, we generated
RNAi-resistant AF-6 and parkin complementary DNAs
(cDNAs), including shRNA-resistant myc-AF-6 encoding
silent mutations at the codons relative to amino acid residues
1138, 1140 and 1141; siRNA-resistant myc-AF-6 with silent
mutations at the codons relative to amino acid residues 842,
843, and 844 as well as shRNA-resistant HA-parkin encoding
silent mutations at the codons relative to amino acid residues
78, 79 and 81. To prove the specificity of RNAis used in this
study, the RNAi-resistant myc-AF-6 and HA-parkin constructs
were co-transfected with their specific RNAis and their ability
to rescue from AF-6 and parkin knockdown were investigated
accordingly.
Figure 5. AF-6 activates parkin ubiquitin-ligase activity at the mitochondria.
(A) HEK293 cells were transfected with HA-parkin and Flag-ubiquitin, in the
presence of either myc-AF-6 or myc-LacZ. Lysates were fractionated into
cytosolic and mitochondrial fractions, and parkin was immunoprecipitated
from each fraction using an anti-HA antibody. Parkin auto-ubiquitination
was determined using an anti-Flag antibody (upper panel). The levels of
HA-parkin immunoprecipitates were determined using an anti-HA antibody
(second panel). The levels of AF-6 and LacZ in the total cells lysates were
determined using an anti-myc antibody (third and fourth panels). (B)
HEK293 cells were transfected and processed as in (A). The levels of auto-
ubiquitinated HA-parkin and total immunoprecipitated HA-parkin were deter-
mined by ImageMaster. The graph shows the quantification of auto-
ubiquitinated HA-parkin relative to immunoprecipitated HA-parkin from cyto-
solic and mitochondrial fractions. Error bars represent standard error of three
independent experiments. ∗∗Significantly different from control at P , 0.01.
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Figure 6. AF-6 increases mitochondrial clustering. (A) SH-SY5Y cells were transfected with GFP-mito, in the presence of myc-parkin (A), PINK1-HA (B) and
myc-parkin together with PINK1-HA (C). Confocal microscopy depicts GFP-mito and DAPI fluorescence. Scale bar, 25 mm. (B) SH-SY5Y cells were trans-
fected with GFP-mito, HA-parkin, PINK1-Flag, in the presence of either myc-AF-6 or myc-LacZ. Immunocytochemistry and confocal microscopy were
carried out with anti-HA (red, A and D) and GFP-mito fluorescence (green, B and E). Scale bar, 25 mm. (C and D) Plots show the quantification of
AF-6-mediated increase in parkin translocation (C) and mitochondrial clustering (D) relative to LacZ. Plots also show the inability of AF-6 to increase
parkin FAA translocation (C) and mitochondrial clustering (D). SH-SY5Y cells were transfected, processed and analyzed as in (B), in the presence of HA-
parkin wild-type or FAA. Error bars represent standard error of 8–12 independent experiments. ∗∗∗Significantly different from LacZ control at P , 0.001.
(E and F) SH-SY5Y cells were transfected with GFP-mito, HA-parkin, PINK1-Flag, with either shRNA control or shRNA to AF-6. Plots show the quantification
of parkin translocation (E) and mitochondrial clustering (F) upon AF-6 knockdown. Transfection of shRNA-resistant myc-AF-6 rescued the effects of shRNA-
mediated AF-6 knockdown on parkin translocation (E) and mitochondrial clustering (F) (gray bars). Error bars represent standard error of four to seven inde-
pendent experiments. ∗∗Significantly different from shRNA control at P , 0.01. (G) SH-SY5Y cells were transfected with shRNA to AF-6 or shRNA control.
The presence of AF-6 in total cell lysates was detected using an anti-AF-6 antibody (upper panel). Loading control was monitored with an anti-actin antibody
(lower panel). (H) SH-SY5Y cells were transfected with shRNA to AF-6 or shRNA control, in the presence of myc-AF-6 or or shRNA-resistant myc-AF-6. The
presence of AF-6 in total cell lysates was detected using anti-AF-6 antibody (upper panel). Loading control was monitored with an anti-actin antibody (lower
panel). (I) HeLa cells stably expressing GFP-parkin were transfected with myc-AF-6 or myc-LacZ. Cells were treated with 10 mM CCCP for 1 h and analyzed by
confocal microscopy to reveal GFP-parkin and its clustering at the mitochondria upon CCCP treatment. Scale bar, 25 mm. (J) The graph shows the quantification
of AF-6-mediated increase in mitochondrial clustering assessed by GFP-parkin fluorescence. HeLa cells stably expressing GFP-parkin were transfected and pro-
cessed as in I. Error bars represent standard error of three independent experiments. ∗∗Significantly different from control at P, 0.01.
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Antibody generation
For anti-AF-6 antibody, rabbits were immunized with the C-
terminal amino acids 849–1190 of AF-6 fused to GST.
Immune serum was passed through a GST-sepharose 4B
column to remove anti-GST antibodies. Pre-cleared serum
was incubated for 16 h with GST-AF-6 (849–1190) immobi-
lized on polyvinylidene fluoride strips. Strips were washed
with 20 mM Tris pH 7.4 and 500 mM NaCl, and the antibody
was eluted from the strips with 100 mM glycine pH 2.5 and
dialyzed against phosphate buffered saline (PBS). For anti-
parkin antibody, rabbits were immunized with the parkin
amino acids 77–237 fused to GST, and the antibody purified
as described above.
Western blot analysis
Samples were homogenized as previously described (58).
Blots were probed with the antibodies mouse anti-HA
(Covance), rabbit anti-myc, rabbit anti-HA, mouse anti-actin,
mouse anti-GAPDH (Santa Cruz), rabbit anti-VDAC (Cell
Signaling), mouse anti-myc, rabbit anti-FLAG and rabbit anti-
parkin (Sigma). Quantifications of enhanced chemilumines-
cence reactions were done according to ImageMaster analysis.
Figure 7. AF-6 increases PINK1/parkin-mediated mitophagy. (A) SH-SY5Y cells were transfected with HA-parkin, PINK1-Flag and GFP, and with either
myc-AF-6 (upper panel) or myc-LacZ (lower panel). Immunocytochemistry was carried out with anti-Tom20 (red, B and E) and GFP fluorescence (green,
A and D). Arrows in (C) indicate transfected cells that lack mitochondria. Scale bar, 25 mm. (B) The graph shows the quantification of transfected cells
lacking mitochondria. SH-SY5Y cells were transfected and analyzed as in (A). Error bars represent standard error of four independent experiments.
(C) SH-SY5Y cells were transfected with HA-parkin, PINK1-Flag and GFP, either with siRNA control or siRNA to AF-6. Transfection of siRNA-resistant
myc-AF-6 rescued the effects of siRNA-mediated AF-6 knockdown (gray bar). Error bars represent standard error of three to six independent experiments.
(D) SH-SY5Y cells were transfected with siRNA to AF-6 or siRNA control. The presence of AF-6 in total cell lysates was detected using an anti-AF-6 antibody
(upper panel). Loading control was monitored with an anti-actin antibody (lower panel). (E) SH-SY5Y cells were transfected with siRNA to AF-6 or siRNA
control, in the presence of myc-AF-6 or siRNA-resistant myc-AF-6. The presence of AF-6 in total cell lysates was detected using an anti-AF-6 antibody
(upper panel). Loading control was monitored with an anti-actin antibody (lower panel). ∗∗, ∗∗∗Significantly different from control at P , 0.01 and 0.001,
respectively.
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For western blot of brain tissues, adult Sprague-Dawley rats
were anesthesized with isoflurane and killed by decapitation
with the approval of the Technion Animal Experimentation
Committee. Brain tissues were homogenized in five volumes/
weight of buffer containing 50 mM Tris pH 7.4, 140 mM KCl,
1% of Triton X-100, 30 mM MG132 (Sigma), and protease
inhibitor cocktail. Samples were centrifuged at 13 000g
and supernatants were collected for further analysis by
western blot.
Post-mortem human brain tissue from four idiopathic PD
and four neurologically normal controls were obtained from
the Queen Square Brain Bank archive (55). Appropriate
written consent was obtained in all cases and the study was
approved by the Local Research Ethics Committee. Brains
were processed as previously described (55). Briefly, substan-
tia nigra and caudate plus putamen of sporadic PD and control
brains were homogenized in buffer containing 50 mM Tris–
HCl, 30 mM NaCl, 30 mM MG132 and protease inhibitor cock-
tail. The extracts were subsequently clarified by centrifugation
at 13 000g for 5 min. The samples (50 mg/lane) were resolved
on PAGE–SDS gels, and the levels of AF-6 and loading con-
trols were determined by western blot analysis.
In vitro binding assays
Extracts of transfected HEK293 cells were homogenized in
50 mM Tris pH 7.4, 140 mM NaCl, 0.5% Triton X-100, 1%
deoxycholate (DOC), 30 mM MG132 and protease inhibitors
cocktail. Lysates were clarified by centrifugation at 13 000g
for 5 min and incubated with GST-fusion protein (5 mg/ml)
coupled to glutathione-agarose (Sigma) for 1 h at 48C. Beads
were washed extensively in lysis buffer containing 500 mM
NaCl. Bound proteins were analyzed by western blot assays.
Co-immunoprecipitation assays
For the co-immunoprecipitation of AF-6 with parkin, trans-
fected cells were lysed in buffer containing 50 mM Tris (pH
7.4), 140 mM NaCl, 1% Triton X-100, 1% DOC, 0.1%
sodium dodecyl sulphate (SDS), 30 mM MG132 and protease
inhibitor cocktail (Complete, Roche). The cell extracts were
clarified by centrifugation and incubated for 4 h with
anti-HA coupled to protein G beads (Sigma) (58). Immunopre-
cipitates were washed with lysis buffer containing 500 mM
NaCl and detected by western blot.
For endogenous co-immunoprecipitation assays, rat brains
were homogenized in buffer containing 50 mM Tris (pH 7.4),
140 mM NaCl, 1% DOC, 1% NP-40, 0.1% SDS, 30 mM
MG132 and protease inhibitor cocktail. Brain homogenates
were clarified by centrifugation at 13 000g for 5 min.
Antibody to parkin was coupled to protein G beads (58) and
incubated for 7 h with brain homogenate (2 mg/ml). Immuno-
precipitates were washed with lysis buffer containing 500 mM
NaCl and detected by western blot using an anti-AF-6
antibody.
In vivo ubiquitination assays
Transfected cells were incubated with 10 mM lactacystin for
12 h, lysed in buffer containing 50 mM Tris pH 7.4, 140 mM
NaCl and 1% SDS, and immediately boiled at 1008C for
5 min. Lysates were sonicated and diluted ten times with
lysis buffer containing 50 mM Tris pH 7.4, 140 mM NaCl,
1% Triton X-100, 30 mM MG132 and protease inhibitor
Figure 8. Effects of AF-6 on parkin and PINK1 familial disease-mutation de-
ficiencies. (A) SH-SY5Y cells were transfected with the indicated Flag-parkin
constructs, wild-type PINK1-HA and GFP-mito, and with either myc-AF-6 or
myc-LacZ. Mitochondrial clustering was determined by analyzing GFP-mito
using confocal microscopy. Error bars represent standard error of three inde-
pendent experiments. ∗∗, ∗∗∗Significantly different from LacZ control at P ,
0.01 and 0.001, respectively. (B) SH-SY5Y cells were transfected with
HA-parkin (wild-type or T240R), PINK1-Flag (wild-type or G309D) and
GFP-mito, and with either myc-AF-6 or myc-LacZ. Parkin localization at
the mitochondria was analyzed by immunocytochemistry with anti-HA and
co-localization with GFP-mito analyzed by confocal microscopy. The graph
shows the quantification of AF-6 effect in the translocation of parkin
T240R. AF-6 did not rescue the deficiency in wild-type parkin translocation
in the presence of PINK1 G309D disease-mutant. Error bars represent standard
error of four independent experiments. ∗∗∗Significantly different from LacZ
control at P , 0.001. (C) Graph shows the quantification of AF-6 effect in
the mitochondrial clustering induced by parkin T240R. AF-6 did not rescue
the mitochondrial clustering deficiency in the presence of G309D mutant.
SH-SY5Y cells were transfected and analyzed as in (B). Error bars represent
standard error of four independent experiments. ∗∗∗Significantly different from
control at P , 0.001.
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cocktail. Samples were centrifuged at 13 000 g for 5 min and
the supernatant was incubated with anti-HA antibody matrix
(Sigma) for 4 h at 48C. Immunoprecipitates were extensively
washed with buffer contained 50 mM Tris pH 7.4, 500 mM
NaCl, 1% Triton X-100 and 0.1% SDS, and detected by
western blot.
Pulse-chase experiments
Transfected cells were pulsed with methionine/cystein-free
medium containing 100 mCi of [35S]methionine/cystein
(Perkin Elmer) for 6 h and subsequently chased in regular
medium for the specified times. The cells were harvested
and immunoprecipitation of HA-AF-6 was carried out as
described above for the co-immunoprecipitation assays.
Immunoprecipitates were resolved on 8% PAGE–SDS gels
and the amount of [35S] labeled-AF-6 was quantified by Phos-
phoImager analysis.
Mitochondrial preparation
Mitochondria were isolated using a discontinuous Percoll gra-
dient as previously described, with a few modifications (59).
Briefly, the cells were disrupted using a glass homogenizer
in buffer containing 250 mM sucrose, 20 mM Hepes, 3 mM
EDTA, 20 mM NaF, 2 mM Na3VO4, 10 mM PPi, 20 mM
b-glycerol phosphate, 30 mM MG132 and protease inhibitor
cocktail. The washed mitochondrial pellet was resuspended
in a 15% Percoll in cold homogenizing buffer, layered onto
a discontinuous Percoll gradient of 23% over 40% and then
centrifuged for 20 min at 73 000g at 48C. The interface band
between the 23 and 40% Percoll layers was collected and
washed twice in cold homogenizing buffer. The mitochondrial
pellet was suspended in homogenization buffer and analyzed
by western blot assays.
For the in vivo ubiquitination experiments using mitochon-
drial fractions, washed Percoll-purified mitochondria was
resuspended in buffer containing 50 mM Tris pH 7.4,
140 mM NaCl, 1% Triton X-100, 0.1% SDS, 30 mM MG132
and protease inhibitor cocktail (Complete, Roche). HA-Parkin
from the mitochondrial fraction was immunoprecipitated,
washed and analyzed by western blot as described for the in
vivo ubiquitination assays.
Immunocytochemistry assays
Transfected SH-SY5Y cells were incubated with or without
10 mM lactacystin, for 12 h, fixed with 4% paraformaldehyde
for 15 min and blocked in PBS containing 0.2% Triton
X-100 and 5% normal goat serum. The cells were labeled
with anti-HA and anti-myc antibodies as previously described
(58). Immunolabeling was detected using FITC- and
Cy3-labeled secondary antibodies (Jackson Laboratories).
The percent of cells containing cytosolic inclusions was
determined by confocal microscopy in at least 20 fields per
experiment.
Figure 9. AF-6 is decreased in PD patients and aggregates into Lewy bodies. (A) Homogenates prepared from different rat brain regions were probed with an
anti-AF-6 antibody (upper panel). Loading control was monitored with an anti-actin antibody (lower panel). (B) Homogenates prepared from control and PD
substantia nigra tissues were probed with an anti-AF-6 antibody (upper panel). Loading control was monitored with an anti-actin antibody (lower panel).
(C) The graph represents the average of AF-6 levels in the substantia nigra shown in (B). Levels of proteins were determined by ImageMaster analysis and
AF-6 were normalized relative to actin. Error bars represent standard error of four different patients. ∗∗Significantly different from control at P , 0.01. (D)
Homogenates prepared from control and PD caudate and putamen tissues were probed with an anti-AF-6 antibody (upper panel). Loading control was monitored
with an anti-actin antibody (lower panel). (E) The Graph represents the average of AF-6 levels in the caudate and putamen shown in (D). Levels of proteins were
determined by ImageMaster analysis and AF-6 were normalized relative to actin. Error bars represent standard error of four different patients. ∗∗Significantly
different from control at P , 0.01. (F) Immunohistochemistry analysis of midbrain sections incubated with a purified anti-AF-6 antibody. Lewy bodies contain-
ing AF-6 are shown in sections from two distinct PD cases (left panels). Right panels show the presence of AF-6 in Lewy neurites. Scale bar is 20 mm.
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The mitochondrial co-localization and clustering experi-
ments in SH-SY5Y cells were carried out by co-transfecting
GFP-mitochondria (GFP-mito; Clontech). The co-localization
of parkin with GFP-mito and the clustering of GFP-mito were
determined by confocal microscopy in at least 20 fields per
experiment. The mitochondrial clustering experiments in
HeLa cells were carried out by co-transfecting stably expres-
sing GFP-parkin HeLa cells, which were then treated with
10 mM CCCP for 1 h and analyzed by confocal microscopy
to reveal GFP–parkin clustering at the mitochondria upon
CCCP treatment.
For the mitophagy experiments, small amounts of GFP were
co-transfected to visualize transfected cells, and mitochondrial
presence was determined by staining endogenous Tom20
mitochondrial protein. The percent of cells lacking mitochon-
dria was determined by confocal microscopy in at least 20
fields per experiment.
The statistics for all the confocal analyses mentioned above
were calculated using paired Student’s t test.
Immunohistochemistry
Immunohistochemistry studies on human brain sections were
carried out using paraffin-embedded formalin-fixed sections
from four idiopathic PD cases (55). Sections (8 mm thick)
were de-waxed and brought to alcoholic phase. Endogenous
peroxidase was blocked using 100% methanol containing
0.3% hydrogen peroxide for 10 min followed by thorough
washing. Pretreatment to unmask antigenic sites involved
pressure cooking the sections in 10 mM citrate buffer for
10 min. Non-specific antigenic sites were blocked using 4%
normal goat serum for 30 min at room temperature (RT).
The AF-6 antibody (1:500) was incubated at first at RT for
1 h followed by overnight incubation at 48C. After washing
the sections thoroughly, a biotinylated secondary antibody
(anti-rabbit broad spectrum antibody Histostain-plus; Zymed)
was incubated at RT for 30 min. The sections were then pro-
cessed by using an ABC-peroxidase kit and diaminobenzidine.
The immunolabeled sections were counterstained lightly with
Meyers’s hematoxylin, dehydrated and coverslip-mounted
with di-n-butylphthalate-polystyrene-xylene.
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